Kailera Therapeutics Q2 EPS $(1.09) Misses $(0.74) Estimate
Kailera Therapeutics (NASDAQ:KLRA) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(0.74) by 47.3 percent.
Stocks · News reference
Jim Cramer Recommends Buying This Energy Stock, Calling It ‘Very Inexpensive’
Jim Cramer favors Texas Pacific Land, calls Kailera his speculative pick, and criticizes P&G, Ondas and Tractor Supply.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Kailera Therapeutics, Inc. (KLRA)
Filed: 2026-08-12 AccNo: 0001193125-26-346919 Size: 411 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
These 10 Stocks Are Squeeze Candidates Waiting to Happen
These 10 heavily shorted stocks face potential reversals, led by Venture Global, followed by CleanSpark and Dutch Bros.
Needham Reiterates Buy on Ondas, Maintains $19 Price Target
Needham analyst Austin Bohlig reiterates Ondas (NASDAQ:ONDS) with a Buy and maintains $19 price target.
Ondas Adds Critical Weapons Tech In $205 Million Deal
Ondas (ONDS) acquires GATE Technologies and Bron for $205M to expand its precision-strike and autonomous defense portfolio.
Ondas Registers 10.7M Shares For Resale By Selling Stockholders Following Acquisition
Ondas Inc.10,689,655 Shares of Common Stock Offered by the Selling StockholdersWe are registering the offer and sale or other disposition from time to time of 10,689,655 shares of our Common Stock ("Common